OutcomeVariable: Nonfatal myocardial infarction or stroke
|
OutcomeVariable: Remission of diabetes
|
OutcomeVariable: New onset depression
|
OutcomeVariable_Treatment_with_opioids
|
OutcomeVariable_Additional_GI_surgical_procedure
|
OutcomeVariable: HbA1c at 12 months
|
OutcomeVariable: HbA1c at 36 months
|
OutcomeVariable: HbA1c at 24 months
|
OutcomeVariable: HbA1c at 60 months
|
OutcomeVariable: HbA1c at 6 months
|
ExposureVariable: Age (as continuous variable)
|
ExposureVariable: Body Mass Index (as continuous variable)
|
ExposureVariable: pht013093.v1.p1 SUBJECT_ID
|
ExposureVariable: pht013093.v1.p1 SEX
|
ExposureVariable: pht013093.v1.p1 RACE
|
ExposureVariable: pht013093.v1.p1 Age at diagnosis
|
ExposureVariable: pht013094.v1.p1 SAMPLE_ID
|
ExposureVariable: pht013094.v1.p1 BODY_SITE
|
ExposureVariable: pht013094.v1.p1 SAMPLE_USE
|
ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
|
ExposureVariable: pht013094.v1.p1 Source_Type
|
ExposureVariable: pht013094.v1.p1 IS_TUMOR
|
NHANES SEQN Respondent Sequence Number
|
NHANES LBXGLU: Fasting Glucose (mg/dL)
|
NHANES LBDGLUSI: Fasting Glucose (mmol/L)
|
NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
|
Median Age of Parachute Intervention Group
|
Age
|
Sex
|
Ethnic Group
|
Height
|
History of Broken Bones
|
History of Acrophobia
|
History of Parachute Use
|
Family History of Parachute Use
|
Frequent Flier
|
International vs Domestic Flight
|
Aircraft Type
|
Velocity
|
Altitude
|
Outcome: Death or Major Traumatic Injury on Impact
|
Outcome: Injury Severity Score on Impact
|
Outcome: Death or Major Traumatic Injury 30 days after Impact
|
Outcome: Injury Severity Score 30 days after Impact
|
Health Survey Score Total
|
Health Survey Score-Physical Health Subscore
|
Health Survey Score-Mental Health Subscore
|
Weight
|
OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
|
VariableDefinition: Gender
|
VariableDefinition: Condition(s)
|
VariableDefinition: Comparator
|
VariableDefinition: Unit
|
VariableDefinition: NTproBNP
|
VariableDefinition: Date of birth
|
VariableDefinition: Date of measurement
|
EvidenceVariable: Time of measurement
|
Time to integration of results in a recommendation
|
EvidenceVariable: Patient id
|
EvidenceVariable: case_id
|
Change in Mean Systolic Blood Pressure (NCT03640312)
|
Mean Systolic Blood Pressure (NCT03640312)
|
Change in Mean Diastolic Blood Pressure (NCT03640312)
|
Mean Diastolic Blood Pressure (NCT03640312)
|
Proportion of Patients With Hypertension Control (NCT03640312)
|
Number of Patients Requiring Step up Treatment (NCT03640312)
|
Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
|
Medication Adherence (NCT03640312)
|
Health-related Quality of Life (NCT03640312)
|
Change in Mean Systolic Blood Pressure (NCT03640312)
|
Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
|
Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
|
Rate of Adverse Events of Special Interest (NCT03640312)
|
Mean Change in Serum Potassium (NCT03640312)
|
Mean Change in Serum Sodium (NCT03640312)
|
Mean Change in Blood Urea Nitrogen (NCT03640312)
|
Mean Change in Serum Creatinine (NCT03640312)
|
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
|
Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
|
Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
|
Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
|
Systolic blood pressure at 12 weeks
|
Diastolic blood pressure at 12 weeks
|
Medication Adherence at 12 weeks
|
Hypertension Control at 12 weeks
|
Add-on Amlodipine at 6 weeks
|
Adverse event free and hypertension control at 12 weeks
|
OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
|
OutcomeVariable_All_cause_mortality
|